Intrust Bank NA Grows Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Intrust Bank NA increased its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 6.9% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 2,823 shares of the company’s stock after buying an additional 183 shares during the quarter. Intrust Bank NA’s holdings in Axsome Therapeutics were worth $239,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. FMR LLC grew its position in shares of Axsome Therapeutics by 20.6% during the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after buying an additional 185,951 shares in the last quarter. Geode Capital Management LLC grew its holdings in Axsome Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 908,459 shares of the company’s stock worth $81,659,000 after acquiring an additional 23,564 shares in the last quarter. Wellington Management Group LLP increased its position in Axsome Therapeutics by 1.1% during the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock valued at $66,750,000 after purchasing an additional 8,125 shares during the period. Norges Bank purchased a new stake in shares of Axsome Therapeutics in the 4th quarter worth approximately $34,100,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Axsome Therapeutics by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company’s stock valued at $27,755,000 after purchasing an additional 5,438 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insiders Place Their Bets

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 22.40% of the stock is currently owned by insiders.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $118.53 on Monday. The business has a fifty day moving average of $119.67 and a 200 day moving average of $101.22. Axsome Therapeutics, Inc. has a 1 year low of $64.11 and a 1 year high of $139.13. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The firm has a market capitalization of $5.78 billion, a price-to-earnings ratio of -19.79 and a beta of 1.00.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. As a group, research analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, March 6th. Bank of America upped their price objective on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. Wells Fargo & Company lifted their target price on Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. William Blair reissued an “outperform” rating on shares of Axsome Therapeutics in a research report on Tuesday, February 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $153.00 price objective on shares of Axsome Therapeutics in a research report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $167.64.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.